Home / Activin A / Human/Mouse/Rat Activin A beta A subunit Antibody

Human/Mouse/Rat Activin A beta A subunit Antibody

Catalog #: MAB3381
25 Citations 2 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB3381-SP
MAB3381-500
MAB3381-100

Save 15% on Select RUO Reagents. See Details. 

Hemoglobin Expression Induced by Activin A and Neutralization by Human/ Mouse/Rat Activin A Antibody.
10 Images
Product Details
Citations (25)
FAQs
Supplemental Products
Reviews (2)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human/Mouse/Rat Activin A beta A subunit Antibody Summary

Species Reactivity
Human, Mouse, Rat
Specificity
Detects recombinant human Activin A in ELISAs. Also recognizes Activin A precursor. The amino acid sequences of mature beta A subunits from human, mouse and rat are identical. Therefore, this antibody will also detect the mature beta A subunit from mouse and rat.
Source
Monoclonal Mouse IgG1 Clone # 69403
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Chinese hamster ovary cell line CHO-derived recombinant human Activin A
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.

Applications

Recommended Concentration
Sample

Human/Mouse/Rat Activin A Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human/Mouse/Rat Activin A beta A subunit Biotinylated Antibody (Catalog # BAM3381)

Neutralization
Measured by its ability to neutralize Activin A-induced hemoglobin expression in the K562 human chronic myelogenous leukemia cell line. The Neutralization Dose (ND50) is typically 0.02-0.06 µg/mL in the presence of 7.5 ng/mL Recombinant Human/Mouse/Rat Activin A.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Hemoglobin Expression Induced by Activin A and Neutralization by Human/ Mouse/Rat Activin A Antibody. View Larger

Hemoglobin Expression Induced by Activin A and Neutralization by Human/ Mouse/Rat Activin A Antibody. Recombinant Human/Mouse/ Rat Activin A (Catalog # 338-AC) increases hemoglobin expression in the K562 human chronic myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the psuedoperoxidase assay. Hemoglobin Expression elicited by Recombinant Human/Mouse/Rat Activin A (7.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human/Mouse/Rat Activin A beta A subunit Monoclonal Antibody (Catalog # MAB3381). The ND50 is typically 0.02-0.06 µg/mL.

Immunohistochemistry Detection of Activin A beta A subunit by Immunohistochemistry View Larger

Detection of Activin A beta A subunit by Immunohistochemistry Activin A levels are significantly higher in tumor tissue and correlate to worse prognosis in PDAC. (A) Representative cores of pancreatic tumors from a human pancreatic tissue microarray stained with H&E to assess the percentage of epithelial versus stromal cells in each core. Adjacent sections were immunostained for activin A expression. (B) Quantification of the percentage of epithelial cells (left panel) or stromal cells (right panel) in normal tissue (white bar) versus tumor tissue (black bar). Statistical analysis is unpaired t-test. (C) Quantification of activin A in TMA (n = 63). An average of the percentage of epithelial and stromal fraction was calculated and scored in each TMA. Comparing epithelial (left panel) and stromal fraction (right panel) in normal tissue (white bar) versus tumor tissue (black bar). Statistical analysis 2-way ANOVA; mean ± SEM, ***(p < 0.001). (D) Kaplan–Meier plots of patient overall survival versus expression of activin A in either epithelial cells (left panel) or stromal cells (right panel). Statistical analysis Log-rank (Mantel-Cox) test, ** (p < 0.01), ***(p < 0.001). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33846512), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Activin A beta A subunit by Immunohistochemistry View Larger

Detection of Activin A beta A subunit by Immunohistochemistry Inhibition of activin A in KPC mice significantly reduces metastasis. (A) Time course of anti-activin A neutralizing antibody injected in mice weekly (2 mg/kg). Control animals were injected with the same concentration of IgG isotype. Remaining animals were collected at the end of week 13 of treatment. (B) Representative image (×4 magnification) of H&E staining of pancreas from control treated (IgG) and anti-activin A treated KPC mice IHC-stained for either alpha -SMA (to indicate stromal cells) or activin A. Representative stromal cells marked by arrows. (C) Representative image (×4 magnification) of H&E staining of pancreas used for quantification of CN (yellow arrow) cystic lesions. Quantification of lesions is documented in both IgG control and anti-activin A antibody treated mice. (D) Left panel: Representative images (×10 and ×40 magnification) of liver tissue from control treated versus anti-activin A treated KPC mice stained with H&E (upper panel) or ductal marker protein CK19 (Lower panel). Right panel: Quantification of distant metastatic formation in the liver tissue of control (n = 5) and treated (n = 7) mice. Statistical analysis unpaired Student t-test (ns: not significant). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33846512), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Activin A beta A subunit by Immunohistochemistry View Larger

Detection of Activin A beta A subunit by Immunohistochemistry Inhibition of activin A in KPC mice significantly reduces metastasis. (A) Time course of anti-activin A neutralizing antibody injected in mice weekly (2 mg/kg). Control animals were injected with the same concentration of IgG isotype. Remaining animals were collected at the end of week 13 of treatment. (B) Representative image (×4 magnification) of H&E staining of pancreas from control treated (IgG) and anti-activin A treated KPC mice IHC-stained for either alpha -SMA (to indicate stromal cells) or activin A. Representative stromal cells marked by arrows. (C) Representative image (×4 magnification) of H&E staining of pancreas used for quantification of CN (yellow arrow) cystic lesions. Quantification of lesions is documented in both IgG control and anti-activin A antibody treated mice. (D) Left panel: Representative images (×10 and ×40 magnification) of liver tissue from control treated versus anti-activin A treated KPC mice stained with H&E (upper panel) or ductal marker protein CK19 (Lower panel). Right panel: Quantification of distant metastatic formation in the liver tissue of control (n = 5) and treated (n = 7) mice. Statistical analysis unpaired Student t-test (ns: not significant). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33846512), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Activin A beta A subunit by Western Blot View Larger

Detection of Activin A beta A subunit by Western Blot Specific activin A inhibition attenuates TGF beta 1-induced Smad3 activation and profibrotic responses in MC. a ELISA demonstrates that TGF beta 1 (24 h) increases actA and actB secretion (n = 3) to 19.5 ng/ml and 2.5 ng/ml, representing an 8.9- and 1.06-fold induction respectively. b TGF beta 1 increases actA in whole cell lysate by 1.8-fold (n = 3). c ActA (20 ng/ml) upregulates FN (n = 3–4), CTGF (n = 4) and alpha SMA (n = 6) at 48 h. d TGF beta 1 and actA both increase Smad3 transcriptional activity; no synergistic effect is seen (n = 6–12). e An actA neutralizing antibody attenuates TGF beta 1-induced FN (n = 5–6), alpha SMA (n = 5), CTGF (n = 5–6), and Smad3 activation (n = 10–12). f ActA neutralization decreases TGF beta 1-induced Smad3 transcriptional activity at 24 h (n = 9–15), but this is not decreased by actB neutralization (n = 6) (g). h MC were stimulated with TGF beta 1 or actA for 1 h, then treated with their type I receptor inhibitor SB431542 (50 µM). Restimulation with the same ligand shows that cells become refractory to TGF beta 1, but not actA (n = 4). *, **, ***, ****P < 0.05, 0.01, 0.001, 0.0001; one-way ANOVA with Tukey’s multiple comparisons post hoc test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36717814), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Activin A beta A subunit by Western Blot View Larger

Detection of Activin A beta A subunit by Western Blot Specific activin A inhibition attenuates TGF beta 1-induced Smad3 activation and profibrotic responses in MC. a ELISA demonstrates that TGF beta 1 (24 h) increases actA and actB secretion (n = 3) to 19.5 ng/ml and 2.5 ng/ml, representing an 8.9- and 1.06-fold induction respectively. b TGF beta 1 increases actA in whole cell lysate by 1.8-fold (n = 3). c ActA (20 ng/ml) upregulates FN (n = 3–4), CTGF (n = 4) and alpha SMA (n = 6) at 48 h. d TGF beta 1 and actA both increase Smad3 transcriptional activity; no synergistic effect is seen (n = 6–12). e An actA neutralizing antibody attenuates TGF beta 1-induced FN (n = 5–6), alpha SMA (n = 5), CTGF (n = 5–6), and Smad3 activation (n = 10–12). f ActA neutralization decreases TGF beta 1-induced Smad3 transcriptional activity at 24 h (n = 9–15), but this is not decreased by actB neutralization (n = 6) (g). h MC were stimulated with TGF beta 1 or actA for 1 h, then treated with their type I receptor inhibitor SB431542 (50 µM). Restimulation with the same ligand shows that cells become refractory to TGF beta 1, but not actA (n = 4). *, **, ***, ****P < 0.05, 0.01, 0.001, 0.0001; one-way ANOVA with Tukey’s multiple comparisons post hoc test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36717814), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Activin A beta A subunit by Immunohistochemistry View Larger

Detection of Activin A beta A subunit by Immunohistochemistry Activin A neutralization inhibits renal fibrosis in TGF beta 1-overexpressing mice. a TGF beta 1 transcript is increased in mice genetically engineered to overexpress TGF beta 1 (HH) compared with wild-type mice (WT) (n = 6–7, *p ≤ 0.05). b Serum actA is elevated in wild-type and HH mice after UUO. This is decreased by treatment with a neutralizing actA antibody (anti-actA) in HH mice. c Renal actA is increased after UUO, with a greater induction in HH mice. Both are attenuated by actA neutralization. Boxed areas are shown at higher magnification immediately below. ActA increases are seen particularly in tubular epithelial cells. d Renal alpha SMA, fibronectin (FN), pSmad3 and MRTF-A are increased after UUO and this is augmented in HH kidneys. Expression of all is attenuated by actA neutralization in both WT and HH kidneys. (n = 6–9) *, **, ***, ****P < 0.05, 0.01, 0.001, 0.0001; one-way ANOVA with Tukey’s multiple comparisons post hoc test where there are > 2 groups; t-test for 2 groups Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36717814), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Activin A beta A subunit by Western Blot View Larger

Detection of Activin A beta A subunit by Western Blot Activin inhibition attenuates TGF beta 1-induced fibrotic responses and Smad3 activation in MC. Activin inhibition with follistatin (FST) decreases TGF beta 1-induced: a FN, alpha SMA and CTGF upregulation at 48 h (n = 5), b Smad3 phosphorylation (pSmad3) at 24 h (n = 5), c Smad3 nuclear translocation as assessed using eGFP-Smad3 (n = 3; 25–30 cells quantified per treatment group) at 24 h, and d Smad3 transcriptional activity at 24 h (n = 8). e Time course experiments show increases in pSmad3 occur earlier (30–60 min) with TGF beta 1 (n = 4) compared with actA (n = 4) or actB (n = 3) (18–48 h). *, **, ***, ****P < 0.05, 0.01, 0.001, 0.0001; one-way ANOVA with Tukey’s multiple comparisons post hoc test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36717814), licensed under a CC-BY license. Not internally tested by R&D Systems.

Western Blot Detection of Activin A beta A subunit by Western Blot View Larger

Detection of Activin A beta A subunit by Western Blot Activin inhibition attenuates TGF beta 1-induced fibrotic responses and Smad3 activation in MC. Activin inhibition with follistatin (FST) decreases TGF beta 1-induced: a FN, alpha SMA and CTGF upregulation at 48 h (n = 5), b Smad3 phosphorylation (pSmad3) at 24 h (n = 5), c Smad3 nuclear translocation as assessed using eGFP-Smad3 (n = 3; 25–30 cells quantified per treatment group) at 24 h, and d Smad3 transcriptional activity at 24 h (n = 8). e Time course experiments show increases in pSmad3 occur earlier (30–60 min) with TGF beta 1 (n = 4) compared with actA (n = 4) or actB (n = 3) (18–48 h). *, **, ***, ****P < 0.05, 0.01, 0.001, 0.0001; one-way ANOVA with Tukey’s multiple comparisons post hoc test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36717814), licensed under a CC-BY license. Not internally tested by R&D Systems.

Immunohistochemistry Detection of Activin A beta A subunit by Immunohistochemistry View Larger

Detection of Activin A beta A subunit by Immunohistochemistry Activin A neutralization inhibits renal fibrosis in TGF beta 1-overexpressing mice. a TGF beta 1 transcript is increased in mice genetically engineered to overexpress TGF beta 1 (HH) compared with wild-type mice (WT) (n = 6–7, *p ≤ 0.05). b Serum actA is elevated in wild-type and HH mice after UUO. This is decreased by treatment with a neutralizing actA antibody (anti-actA) in HH mice. c Renal actA is increased after UUO, with a greater induction in HH mice. Both are attenuated by actA neutralization. Boxed areas are shown at higher magnification immediately below. ActA increases are seen particularly in tubular epithelial cells. d Renal alpha SMA, fibronectin (FN), pSmad3 and MRTF-A are increased after UUO and this is augmented in HH kidneys. Expression of all is attenuated by actA neutralization in both WT and HH kidneys. (n = 6–9) *, **, ***, ****P < 0.05, 0.01, 0.001, 0.0001; one-way ANOVA with Tukey’s multiple comparisons post hoc test where there are > 2 groups; t-test for 2 groups Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36717814), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Activin A

Activin and Inhibin are members of the TGF-beta superfamily of cytokines and are involved in a wide range of biological processes including tissue morphogenesis and repair, fibrosis, inflammation, neural development, hematopoiesis, reproductive system function, and carcinogenesis (1‑7). Activin and Inhibin are produced as precursor proteins. Their amino terminal propeptides are proteolytically cleaved and facilitate formation of disulfide-linked dimers of the bioactive proteins (8, 9). Activins are nonglycosylated homodimers or heterodimers of various beta  subunits ( beta A, beta B, beta C, and beta E in mammals), while Inhibins are heterodimers of a unique alpha  subunit and one of the beta  subunits. Activin A is a widely expressed homodimer of two beta A chains. The beta A subunit can also heterodimerize with a beta B or beta C subunit to form Activin AB and Activin AC, respectively (10). The 14 kDa mature human beta A chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat beta A. Activin A exerts its biological activities by binding to the type 2 serine/threonine kinase Activin RIIA which then noncovalently associates with the type 1 serine/threonine kinase Activin RIB/ALK-4 (7, 11). Signaling through this receptor complex leads to Smad activation and regulation of activin-responsive gene transcription (7, 11). The bioactivity of Activin A is regulated by a variety of mechanisms (11). BAMBI, Betaglycan, and Cripto are cell-associated molecules that function as decoy receptors or limit the ability of Activin A to induce receptor complex assembly (12‑14). The intracellular formation of Activin A can be prevented by the incorporation of the beta A subunit into Activin AC or Inhibin A (3, 10). And the bioavailability of Activin A is restricted by its incorporation into inactive complexes with alpha 2-Macroglobulin, Follistatin, and FLRG (15, 16).

References
  1. Kumanov, P. et al. (2005) Reprod. Biomed. Online 10:786.
  2. Maeshima, A. et al. (2008) Endocr. J. 55:1.
  3. Rodgarkia-Dara, C. et al. (2006) Mutat. Res. 613:123.
  4. Werner, S. and C. Alzheimer (2006) Cytokine Growth Factor Rev. 17:157.
  5. Xu, P. and A.K. Hall (2006) Dev. Biol. 299:303.
  6. Shav-Tal, Y. and D. Zipori (2002) Stem Cells 20:493.
  7. Chen, Y.G. et al. (2006) Exp. Biol. Med. 231:534.
  8. Gray, A.M. and A.J. Mason (1990) Science 247:1328.
  9. Mason, A.J. et al. (1996) Mol. Endocrinol. 10:1055.
  10. Thompson, T.B. et al. (2004) Mol. Cell. Endocrinol. 225:9.
  11. Harrison, C.A. et al. (2005) Trends Endocrinol. Metab. 16:73.
  12. Onichtchouk, D. et al. (1999) Nature 401:480.
  13. Gray, P.C. et al. (2002) Mol. Cell. Endocrinol. 188:254.
  14. Kelber, J.A. et al. (2008) J. Biol. Chem. 283:4490.
  15. Phillips, D.J. et al. (1997) J. Endocrinol. 155:65.
  16. Schneyer, A. et al. (2003) Endocrinology 144:1671.
Entrez Gene IDs
3624 (Human); 16323 (Mouse); 29200 (Rat)
Alternate Names
Activin A; activin AB alpha polypeptide; Activin beta-A chain; erythroid differentiation factor; Erythroid differentiation protein; follicle-stimulating hormone-releasing protein; FSH-releasing protein; inhibin beta A chain; inhibin beta A subunit; Inhibin, beta-1

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human/Mouse/Rat Activin A beta A subunit Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

25 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Overexpression of CD36 in mammary fibroblasts suppresses colony growth in breast cancer cell lines
    Authors: Qingsu Cheng, Kosar Jabbari, Garrett Winkelmaier, Cody Andersen, Paul Yaswen, Mina Khoshdeli et al.
    Biochemical and Biophysical Research Communications
  2. A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells
    Authors: Xudong Di, Danica M.K. Andrews, Charles J. Tucker, Linda Yu, Alicia B. Moore, Xiaolin Zheng et al.
    Experimental & Molecular Medicine
  3. Activin A-Smad Signaling Mediates Connective Tissue Growth Factor Synthesis in Liver Progenitor Cells
    Authors: Ze-Yang Ding, Guan-Nan Jin, Wei Wang, Yi-Min Sun, Wei-Xun Chen, Lin Chen et al.
    International Journal of Molecular Sciences
  4. Sox9 inhibits Activin A to promote biliary maturation and branching morphogenesis
    Authors: Hrncir, HR;Goodloe, B;Bombin, S;Hogan, CB;Jadi, O;Gracz, AD;
    Nature communications
    Species: Mouse
    Sample Types: In Vivo, Organoid
    Applications: Immunohistochemistry, In vivo assay
  5. Sox9 links biliary maturation to branching morphogenesis
    Authors: Hrncir, HR;Bombin, S;Goodloe, B;Hogan, CB;Jadi, O;Gracz, AD;
    bioRxiv : the preprint server for biology
    Applications: In Vivo, IHC
  6. GDF8 Contributes to Liver Fibrogenesis and Concomitant Skeletal Muscle Wasting
    Authors: Culver, A;Hamang, M;Wang, Y;Jiang, H;Yanum, J;White, E;Gawrieh, S;Vuppalanchi, RK;Chalasani, NP;Dai, G;Yaden, BC;
    Biomedicines
    Species: Mouse
    Sample Types:
    Applications: In Vivo
  7. Orally-active, clinically-translatable senolytics restore alpha-Klotho in mice and humans
    Authors: Y Zhu, LGPL Prata, EOW Gerdes, JME Netto, T Pirtskhala, N Giorgadze, U Tripathi, CL Inman, KO Johnson, A Xue, AK Palmer, T Chen, K Schaefer, JN Justice, AM Nambiar, N Musi, SB Kritchevsk, J Chen, S Khosla, D Jurk, MJ Schafer, T Tchkonia, JL Kirkland
    EBioMedicine, 2022-03-13;0(0):103912.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  8. Role of stromal activin A in human pancreatic cancer and metastasis in mice
    Authors: G Mancinelli, C Torres, N Krett, J Bauer, K Castellano, R McKinney, D Dawson, G Guzman, R Hwang, S Grimaldo, P Grippo, B Jung
    Scientific Reports, 2021-04-12;11(1):7986.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC, Neutralization
  9. Activin A programs the differentiation of human TFH cells
    Nat Immunol, 2016-07-04;17(8):976-84.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Activin A-Smad Signaling Mediates Connective Tissue Growth Factor Synthesis in Liver Progenitor Cells
    Authors: Ze-Yang Ding, Guan-Nan Jin, Wei Wang, Yi-Min Sun, Wei-Xun Chen, Lin Chen et al.
    International Journal of Molecular Sciences
    Species: Human
    Sample Types: Whole Tissue
    Applications: Neutralization
  11. Low miR-143/miR-145 Cluster Levels Induce Activin A Overexpression in Oral Squamous Cell Carcinomas, Which Contributes to Poor Prognosis.
    Authors: Bufalino A, Cervigne N, de Oliveira C, Fonseca F, Rodrigues P, Macedo C, Sobral L, Miguel M, Lopes M, Paes Leme A, Lambert D, Salo T, Kowalski L, Graner E, Coletta R
    PLoS ONE, 2015-08-28;10(8):e0136599.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  12. Adipose Stromal Cell Contact with Endothelial Cells Results in Loss of Complementary Vasculogenic Activity Mediated by Induction of Activin A.
    Authors: Merfeld-Clauss S, Lupov I, Lu H, March K, Traktuev D
    Stem Cells, 2015-07-03;33(10):3039-51.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Neutralization
  13. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile.
    Authors: Sierra-Filardi E, Nieto C, Dominguez-Soto A, Barroso R, Sanchez-Mateos P, Puig-Kroger A, Lopez-Bravo M, Joven J, Ardavin C, Rodriguez-Fernandez J, Sanchez-Torres C, Mellado M, Corbi A
    J Immunol, 2014-03-17;192(8):3858-67.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Blocking
  14. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers.
    Authors: Sierra-Filardi E, Puig-Kroger A, Blanco FJ, Nieto C, Bragado R, Palomero MI, Bernabeu C, Vega MA, Corbi AL
    Blood, 2011-03-09;117(19):5092-101.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  15. Activin A is an anticatabolic autocrine cytokine in articular cartilage whose production is controlled by fibroblast growth factor 2 and NF-kappaB.
    Authors: Alexander S, Watt F, Sawaji Y, Hermansson M, Saklatvala J
    Arthritis Rheum., 2007-11-01;56(11):3715-25.
    Species: Human, Porcine
    Sample Types: Whole Cells
    Applications: Neutralization
  16. The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases.
    Authors: Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Blumenfeld Z
    J. Neurochem., 2007-08-06;103(3):962-71.
    Species: Human, Rat
    Sample Types: Cell Lysates
    Applications: Western Blot
  17. Fibroblast growth factor 2 modulates transforming growth factor beta signaling in mouse embryonic fibroblasts and human ESCs (hESCs) to support hESC self-renewal.
    Authors: Greber B, Lehrach H, Adjaye J
    Stem Cells, 2006-10-12;25(2):455-64.
    Species: Mouse
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  18. Requirement of Smad3 for mast cell growth.
    Authors: Funaba M, Nakaya K, Ikeda T, Murakami M, Tsuchida K, Sugino H
    Cell. Immunol., 2006-07-12;240(1):47-52.
    Species: Mouse
    Sample Types: Cell Lysates, Whole Cells
    Applications: Neutralization, Western Blot
  19. N-cadherin is regulated by activin A and associated with tumor aggressiveness in esophageal carcinoma.
    Authors: Utsunomiya T, Sonoda H, Mimori K
    Clin. Cancer Res., 2004-09-01;10(17):5702-7.
    Species: Human
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  20. Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia
    Authors: Kristine Pettersen, Sonja Andersen, Anna van der Veen, Unni Nonstad, Shinji Hatakeyama, Christian Lambert et al.
    Journal of Cachexia, Sarcopenia and Muscle
  21. Targeting senescent cells enhances adipogenesis and metabolic function in old age
    Authors: Ming Xu, Allyson K Palmer, Husheng Ding, Megan M Weivoda, Tamar Pirtskhalava, Thomas A White et al.
    eLife
  22. Activin a promotes myofibroblast differentiation of endometrial mesenchymal stem cells via STAT3-dependent Smad/CTGF pathway
    Authors: Zhenzhen Zhang, Jing Wang, Yabing Chen, Luxuan Suo, Huixian Chen, Li Zhu et al.
    Cell Communication and Signaling
  23. The role of activins in hepcidin regulation during malaria
    Authors: N Spottiswoo, AE Armitage, AR Williams, AJ Fyfe, S Biswas, SH Hodgson, D Llewellyn, P Choudhary, SJ Draper, P Duffy, H Drakesmith
    Infect. Immun., 2017-11-17;0(0):.
  24. Activin B promotes the initiation and progression of liver fibrosis
    Authors: Yan Wang, Matthew Hamang, Alexander Culver, Huaizhou Jiang, Jennifer Yanum, Veronica Garcia et al.
    Hepatology Communications
  25. The Activin A-Peroxisome Proliferator-Activated Receptor Gamma Axis Contributes to the Transcriptome of GM-CSF-Conditioned Human Macrophages
    Authors: Concha Nieto, Rafael Bragado, Cristina Municio, Elena Sierra-Filardi, Bárbara Alonso, María M. Escribese et al.
    Frontiers in Immunology

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human/Mouse/Rat Activin A beta A subunit Antibody

Average Rating: 5 (Based on 2 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human/Mouse/Rat Activin A beta A subunit Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human/Mouse/Rat Activin A beta A subunit Antibody
By Anonymous on 07/07/2020
Application: B/N Sample Tested: Serum-free Cell Culture Supernates Species: Human

We used this INHBA (100ng/mL) neutralizing antibody as part of an antibody cocktail containing several other antibodies to neutralize INHBA present in the Conditioned Medium (CM) from BT549 Cells treated with Angiotensin II. The effect of cytokines in the CM (+/-Neutralizing ab Cocktail) on Endothelial (HUVEC) Cell migration was measured using Incucyte Zoom Chemotaxis Assay.

Block/Neutralize Human/Mouse/Rat Activin A beta A subunit Antibody MAB3381
Human/Mouse/Rat Activin A beta A subunit Antibody
By Anonymous on 03/28/2019
Application: ELISA Sample Tested: Recombinant protein Species: Human

I added a sulfo tag to this antibody and used it as a detection antibody when developing an immunoassay for Activin A.

ELISA Human/Mouse/Rat Activin A beta A subunit Antibody MAB3381